Association between process performance measures and 1-year mortality among patients with incident heart failure: a Danish nationwide study.
Adrenergic beta-Antagonists
/ therapeutic use
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Denmark
/ epidemiology
Echocardiography
Exercise Therapy
Female
Follow-Up Studies
Guideline Adherence
Heart Failure
/ diagnostic imaging
Humans
Male
Middle Aged
Patient Education as Topic
Practice Guidelines as Topic
Process Assessment, Health Care
Registries
Treatment Outcome
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
12
11
2017
accepted:
10
09
2018
pubmed:
12
9
2018
medline:
7
2
2019
entrez:
12
9
2018
Statut:
ppublish
Résumé
To examine the association between fulfilment of performance measures supported by clinical guidelines recommendations and 1-year mortality among patients with incident heart failure (HF) in Denmark. A nationwide population-based follow-up study based on the Danish Heart Failure Registry. All Danish hospital departments caring for patients with HF. We identified 24 308 in- and outpatients diagnosed with HF from 2003 to 2010. Quality of care was defined as receiving the guideline recommended processes of care: use of echocardiography, New York Heart Association classification, treatment with angiotensin-converting-enzyme inhibitors/angiotensin-II-receptor blocker, beta blockers, physical training, and patient education. Main outcome measure is 1-year mortality. We used multiple imputation and multivariable Cox proportional hazard regression to compute hazard ratios (HRs) for 1-year mortality adjusted for potential confounding factors. Within 1 year, 17.1% of the patients died and the adjusted HRs ranged from 0.61 [95% confidence interval (CI) 0.55-0.67] for patient education to 0.99 (95% CI 0.90-1.10) for beta blocker therapy. The association between meeting more performance measures and 1-year mortality appeared to follow a dose-response pattern: using 0-25% of fulfilled measures as reference, patients who fulfilled 76-100% of the performance measures had an adjusted HR of 0.43 (95% CI 0.38-0.48), while the adjusted HR was 0.96 (95% CI 0.86-1.07) for patients who fulfilled between 26% and 50% of the performance measures. Meeting process performance measures, which reflect care in concordance with clinical guideline recommendations, was associated with substantially lower 1-year mortality among patients with incident HF.
Identifiants
pubmed: 30204858
pii: 5094885
doi: 10.1093/ehjqcco/qcy041
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin II Type 1 Receptor Blockers
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-34Commentaires et corrections
Type : CommentIn